BAF57 활성제

Z39Ig Activators are a collection of compounds that indirectly enhance the activity of Z39Ig, a protein encoded by the VSIG4 gene and implicated in immune regulation. Cyclosporin A and FK-506, both immunosuppressants, play a pivotal role in enhancing Z39Ig's functionality. They achieve this by modulating T-cell responses, which aligns with Z39Ig's role as a negative regulator of T-cell activation. Cyclosporin A, specifically, inhibits calcineurin, thereby indirectly supporting Z39Ig's function in immune suppression. Similarly, corticosteroids like Dexamethasone and Hydrocortisone enhance Z39Ig activity through their anti-inflammatory effects, potentially increasing the expression or stability of Z39Ig and thus augmenting its role in downregulating immune responses.

Furthermore, compounds such as Cholecalciferol and Retinoic Acid contribute to the functionality of Z39Ig by influencing immune cell differentiation and gene expression. Cholecalciferol, for instance, can modulate the expression of genes like VSIG4, potentially upregulating Z39Ig expression and enhancing its immunosuppressive role. Retinoic Acid, all trans also plays a similar role by affecting gene expression patterns. Additionally, immunomodulatory agents like Rapamycin, Mycophenolate Mofetil, Azathioprine, and Methotrexate support Z39Ig's function by creating an immunosuppressive environment, either through inhibiting lymphocyte proliferation or by modulating immune responses. Prednisolone and Aspirin, with their roles in reducing inflammation and modulating immune responses, further aid in enhancing Z39Ig's role in immune regulation. Collectively, these Z39Ig Activators, through their varied mechanisms of action, support and augment the role of Z39Ig in immune suppression.